mProX™ Human NECTIN2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NECTIN2, also known as CD112, is a gene that has been studied in various fields, including Alzheimer's disease (AD), cancer immunotherapy, acute myeloid leukemia (AML), and polycystic ovary syndrome (PCOS). In the context of AD, a study found that the pneumococcal polysaccharide vaccine, which targets pneumonia, was associated with lower odds of AD in carriers of a specific genetic variant (rs6859 A allele) in the NECTIN2 gene. This suggests that the vaccine may provide genotype-specific protection against AD. In cancer immunotherapy, NECTIN2 is recognized by the DNAM-1 receptor on natural killer (NK) cells, and its interaction with NECTIN2-expressing cancer cells can trigger inhibitory signals via immune checkpoint receptors, such as TIGIT. Targeting this interaction has shown promise in improving anti-tumor immune responses. In AML, the DNAM-1/CD112 axis, which involves NECTIN2, has been identified as a potential target for NK-cell therapy. Modifying this axis in NK cells enhances their cytotoxic activity against AML cells. In PCOS, differential methylation and expression of NECTIN2 have been observed in ovarian granulosa cells of PCOS patients compared to healthy controls, suggesting its involvement in the molecular abnormalities of PCOS. Overall, NECTIN2 has implications in personalized prevention of AD, cancer immunotherapy, AML therapy, and understanding the pathogenesis of PCOS.